{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:32:00Z","timestamp":1792067520292,"version":"4.4.0"},"reference-count":316,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"DOI":"10.1002\/ejhf.654","type":"journal-article","created":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T03:32:47Z","timestamp":1472268767000},"page":"9-42","source":"Crossref","is-referenced-by-count":327,"title":["2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines"],"prefix":"10.1093","volume":"19","author":[{"given":"Jose Luis","family":"Zamorano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodriguez Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lopez Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo F.","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bar\u00f3n-Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scipione","family":"Carerj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7etin","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gaemperli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kolh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Nihoyannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo F.","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Vaz Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,27]]},"reference":[{"key":"2026080802431612500_ejhf654-bib-0001","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0002","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2026080802431612500_ejhf654-bib-0003","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0004","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0005","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0006","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0007","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2026080802431612500_ejhf654-bib-0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026080802431612500_ejhf654-bib-0010","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0011","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijcard.2013.03.133","article-title":"Cardioncology: state of the heart","volume":"168","author":"Todaro","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0013","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2026080802431612500_ejhf654-bib-0014","first-page":"869","article-title":"Chemotherapy-induced cardiotoxicity: detection, prevention, and management","volume":"30","author":"Truong","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12012-012-9164-0","article-title":"Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review","volume":"12","author":"Svoboda","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"2026080802431612500_ejhf654-bib-0016","first-page":"482","article-title":"Cardiovascular toxicity of biologic agents for cancer therapy","volume":"28","author":"Bhave","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"2026080802431612500_ejhf654-bib-0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","article-title":"Cardiac toxicity from systemic cancer therapy: a comprehensive review","volume":"53","author":"Curigliano","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026080802431612500_ejhf654-bib-0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0019","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment","volume":"37","author":"Senkus","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2026080802431612500_ejhf654-bib-0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2026080802431612500_ejhf654-bib-0021","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jnci\/djn206","article-title":"New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients","volume":"100","author":"Ryberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0022","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"2026080802431612500_ejhf654-bib-0023","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0024","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0025","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0002-9343(78)90802-1","article-title":"Early anthracycline cardiotoxicity","volume":"65","author":"Bristow","year":"1978","journal-title":"Am J Med"},{"key":"2026080802431612500_ejhf654-bib-0026","first-page":"4543","article-title":"Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res"},{"key":"2026080802431612500_ejhf654-bib-0027","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J Biol Chem"},{"key":"2026080802431612500_ejhf654-bib-0028","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"2026080802431612500_ejhf654-bib-0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","article-title":"Anthracycline-induced cardiotoxicity","volume":"125","author":"Shan","year":"1996","journal-title":"Ann Intern Med"},{"issue":"(Suppl 2)","key":"2026080802431612500_ejhf654-bib-0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1047951115000906","article-title":"Cardiac complications in childhood cancer survivors treated with anthracyclines","volume":"25","author":"Franco","year":"2015","journal-title":"Cardiol Young"},{"key":"2026080802431612500_ejhf654-bib-0031","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0032","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?","volume":"53","author":"Sawyer","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026080802431612500_ejhf654-bib-0033","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0034","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"2026080802431612500_ejhf654-bib-0035","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0036","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026080802431612500_ejhf654-bib-0038","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0039","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0040","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens","volume":"9","author":"Braverman","year":"1991","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0041","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","article-title":"Cardiotoxicity associated with high-dose cyclophosphamide therapy","volume":"141","author":"Gottdiener","year":"1981","journal-title":"Arch Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0043","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.1295","article-title":"Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience","volume":"93","author":"Gollerkeri","year":"2001","journal-title":"Int J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0044","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0046","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2014.60.1799","article-title":"Update on metastatic gastric and esophageal cancers","volume":"33","author":"Shah","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0047","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0048","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"2026080802431612500_ejhf654-bib-0049","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0050","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0051","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0052","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0053","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","article-title":"ERBB2 inhibition and heart failure","volume":"367","author":"Cote","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0054","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","article-title":"Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?","volume":"4","author":"de Azambuja","year":"2009","journal-title":"Target Oncol"},{"key":"2026080802431612500_ejhf654-bib-0056","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2026080802431612500_ejhf654-bib-0057","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0058","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0059","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","article-title":"Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab","volume":"23","author":"Lenihan","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0061","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0062","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0063","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"2026080802431612500_ejhf654-bib-0064","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2026080802431612500_ejhf654-bib-0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080802431612500_ejhf654-bib-0066","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0067","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026080802431612500_ejhf654-bib-0068","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0069","first-page":"106","article-title":"Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities","author":"Shelburne","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"2026080802431612500_ejhf654-bib-0071","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0072","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"2026080802431612500_ejhf654-bib-0073","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0074","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2026080802431612500_ejhf654-bib-0075","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-drug discovery and cardiovascular surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0076","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0077","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction\u2014Alzheimer's disease of the heart?","volume":"368","author":"Willis","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0078","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4250.4250","article-title":"Serial echocardiographic assessment of patients (pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 Endeavor Trial (NCT01568866)","volume":"126","author":"Russell","year":"2015","journal-title":"Blood"},{"key":"2026080802431612500_ejhf654-bib-0079","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4257.4257","article-title":"Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy","volume":"126","author":"Lendvai","year":"2015","journal-title":"Blood"},{"key":"2026080802431612500_ejhf654-bib-0080","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0081","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"2026080802431612500_ejhf654-bib-0082","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djk064","article-title":"Long-term risk of cardiovascular disease in 10-year survivors of breast cancer","volume":"99","author":"Hooning","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0083","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0084","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026080802431612500_ejhf654-bib-0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0086","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcad.2010.04.002","article-title":"Role of biomarkers in chemotherapy-induced cardiotoxicity","volume":"53","author":"Cardinale","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026080802431612500_ejhf654-bib-0087","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0088","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0089","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0090","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0091","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0092","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0093","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0094","first-page":"11","volume-title":"Cancer and the Heart","author":"Ewer","year":"2013"},{"key":"2026080802431612500_ejhf654-bib-0095","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0096","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080802431612500_ejhf654-bib-0098","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0002-9149(03)00546-0","article-title":"Echocardiographic features of radiation-associated valvular disease","volume":"92","author":"Hering","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0099","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"2026080802431612500_ejhf654-bib-0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0101","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080802431612500_ejhf654-bib-0103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjci\/jeu184","article-title":"Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging","volume":"16","author":"Voigt","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-94-4-430","article-title":"Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography","volume":"94","author":"Gottdiener","year":"1981","journal-title":"Ann Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0105","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0106","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12350-013-9707-1","article-title":"Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively","volume":"20","author":"Schwartz","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0107","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review","volume":"6","author":"Thavendiranathan","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/157340310791162668","article-title":"Cardiac MRI in infiltrative disorders: a concise review","volume":"6","author":"Penugonda","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"2026080802431612500_ejhf654-bib-0109","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","journal-title":"JAMA"},{"key":"2026080802431612500_ejhf654-bib-0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hfc.2011.03.002","article-title":"Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy","volume":"7","author":"Ky","year":"2011","journal-title":"Heart Fail Clin"},{"key":"2026080802431612500_ejhf654-bib-0111","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0112","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0113","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2026080802431612500_ejhf654-bib-0114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy-induced left ventricular dysfunction: interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"J Card Fail"},{"key":"2026080802431612500_ejhf654-bib-0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026080802431612500_ejhf654-bib-0116","first-page":"151","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"2026080802431612500_ejhf654-bib-0117","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","volume":"13","author":"Frickhofen","year":"2002","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0118","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0119","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0120","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0121","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Huddart","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0122","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0123","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0124","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0125","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","article-title":"Sorafenib-induced acute myocardial infarction due to coronary artery spasm","volume":"54","author":"Arima","year":"2009","journal-title":"J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2011.06.016","article-title":"Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden","volume":"100","author":"McGale","year":"2011","journal-title":"Radiother Oncol"},{"key":"2026080802431612500_ejhf654-bib-0127","first-page":"163","article-title":"Comparative pathology: radiation-induced coronary artery disease in man and animals","volume":"3","author":"Virmani","year":"1998","journal-title":"Semin Interv Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0002-9343(81)90574-X","article-title":"Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart","volume":"70","author":"Brosius","year":"1981","journal-title":"Am J Med"},{"key":"2026080802431612500_ejhf654-bib-0129","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0046-8177(96)90447-5","article-title":"Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases","volume":"27","author":"Veinot","year":"1996","journal-title":"Hum Pathol"},{"key":"2026080802431612500_ejhf654-bib-0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/0002-9149(87)90345-6","article-title":"Clinical and angiographic features of coronary artery disease after chest irradiation","volume":"60","author":"McEniery","year":"1987","journal-title":"Am J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0131","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0360-3016(96)00295-7","article-title":"Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease","volume":"36","author":"King","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802431612500_ejhf654-bib-0132","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0133","first-page":"492","article-title":"Coronary artery dosimetry in intact left breast irradiation","volume":"7","author":"Storey","year":"2001","journal-title":"Cancer J"},{"key":"2026080802431612500_ejhf654-bib-0134","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2006.08.6595","article-title":"Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer","volume":"25","author":"Correa","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0958-3947(91)90089-K","article-title":"Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin's disease","volume":"16","author":"Vijayakumar","year":"1991","journal-title":"Med Dosim"},{"key":"2026080802431612500_ejhf654-bib-0136","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/hrt.69.6.496","article-title":"Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment","volume":"69","author":"Orzan","year":"1993","journal-title":"Br Heart J"},{"key":"2026080802431612500_ejhf654-bib-0137","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0138","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0139","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0141","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0142","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2012.46.6086","article-title":"Endothelial damage in long-term survivors of childhood cancer","volume":"31","author":"Brouwer","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0143","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(09)70287-6","article-title":"The metabolic syndrome in cancer survivors","volume":"11","author":"de Haas","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0144","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/cncr.22965","article-title":"Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment","volume":"110","author":"Prosnitz","year":"2007","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0145","first-page":"286","article-title":"Detection of radiation-induced myocardial damage by technetium-99 m sestamibi scintigraphy","volume":"24","author":"Gyenes","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"108","key":"2026080802431612500_ejhf654-bib-0146","first-page":"e101","article-title":"Radiotherapy-induced mitral stenosis: a three-dimensional perspective","volume":"23","author":"Malanca","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080802431612500_ejhf654-bib-0147","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0148","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0149","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS)","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer chemotherapy and cardiac arrhythmias: a review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf"},{"key":"2026080802431612500_ejhf654-bib-0151","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"2026080802431612500_ejhf654-bib-0152","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0153","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"2026080802431612500_ejhf654-bib-0154","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0156","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0157","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","article-title":"What clinicians should know about the QT interval","volume":"289","author":"Al-Khatib","year":"2003","journal-title":"JAMA"},{"key":"2026080802431612500_ejhf654-bib-0158","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1158\/1078-0432.CCR-06-1017","article-title":"Challenges of evaluating the cardiac effects of anticancer agents","volume":"12","author":"Bates","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2026080802431612500_ejhf654-bib-0159","doi-asserted-by":"crossref","first-page":"e114445","DOI":"10.1371\/journal.pone.0114445","article-title":"Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes","volume":"9","author":"Larsen","year":"2014","journal-title":"PLoS One"},{"key":"2026080802431612500_ejhf654-bib-0160","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/EDE.0b013e3182300720","article-title":"Hypertension and risk of renal cell carcinoma among white and black Americans","volume":"22","author":"Colt","year":"2011","journal-title":"Epidemiology"},{"key":"2026080802431612500_ejhf654-bib-0161","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/ijc.28334","article-title":"Arterial hypertension and cancer","volume":"134","author":"Milan","year":"2014","journal-title":"Int J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0162","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0163","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0164","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"key":"2026080802431612500_ejhf654-bib-0166","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0167","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"2026080802431612500_ejhf654-bib-0168","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jhh.2013.30","article-title":"Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis","volume":"27","author":"Funakoshi","year":"2013","journal-title":"J Hum Hypertens"},{"key":"2026080802431612500_ejhf654-bib-0169","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026080802431612500_ejhf654-bib-0170","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2125.2012.04417.x","article-title":"Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials","volume":"75","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026080802431612500_ejhf654-bib-0171","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00228-013-1598-1","article-title":"Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis","volume":"70","author":"Wang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2026080802431612500_ejhf654-bib-0172","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0173","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0174","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/01.HYP.0000239816.13007.c9","article-title":"Effect of regular phosphodiesterase type 5 inhibition in hypertension","volume":"48","author":"Oliver","year":"2006","journal-title":"Hypertension"},{"key":"2026080802431612500_ejhf654-bib-0175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0176","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"2026080802431612500_ejhf654-bib-0177","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000093551","article-title":"Mechanisms of cancer-induced thrombosis in cancer","volume":"35","author":"Rickles","year":"2006","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2026080802431612500_ejhf654-bib-0178","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2010.10.001","article-title":"Arterial thrombosis in ambulatory cancer patients treated with chemotherapy","volume":"127","author":"Di Nisio","year":"2011","journal-title":"Thromb Res"},{"key":"2026080802431612500_ejhf654-bib-0179","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/cncr.24219","article-title":"A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health","volume":"115","author":"Ewer","year":"2009","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0180","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1160\/TH13-02-0131","article-title":"High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080802431612500_ejhf654-bib-0181","doi-asserted-by":"crossref","first-page":"789","DOI":"10.6004\/jnccn.2011.0064","article-title":"Risk assessment and prophylaxis for VTE in cancer patients","volume":"9","author":"Khorana","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"2026080802431612500_ejhf654-bib-0182","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0183","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis","volume":"118","author":"Haddad","year":"2006","journal-title":"Thromb Res"},{"key":"2026080802431612500_ejhf654-bib-0184","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.6004\/jnccn.2014.0155","article-title":"Approach to the management of incidental venous thromboembolic events in patients with cancer","volume":"12","author":"O'Connell","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"2026080802431612500_ejhf654-bib-0185","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","volume":"7","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0186","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0187","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0188","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"2026080802431612500_ejhf654-bib-0189","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH14-11-0977","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"Schulman","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026080802431612500_ejhf654-bib-0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/TCRM.S49063","article-title":"New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients","volume":"10","author":"Gerotziafas","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"2026080802431612500_ejhf654-bib-0191","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026080802431612500_ejhf654-bib-0192","first-page":"2865","article-title":"Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial","volume":"20","author":"Barginear","year":"2012","journal-title":"Support Care Cancer"},{"key":"2026080802431612500_ejhf654-bib-0193","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jmv.2013.09.003","article-title":"[Arterial bypass iterative thrombosis and cancer: three cases]","volume":"39","author":"Villemur","year":"2014","journal-title":"J Mal Vasc"},{"key":"2026080802431612500_ejhf654-bib-0194","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1161\/STROKEAHA.111.615203","article-title":"Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review","volume":"42","author":"Plummer","year":"2011","journal-title":"Stroke"},{"key":"2026080802431612500_ejhf654-bib-0195","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0196","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2006.06.043","article-title":"Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes","volume":"66","author":"Yuan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802431612500_ejhf654-bib-0197","first-page":"94","article-title":"Chronic damage to medium and large arteries following irradiation","volume":"25","author":"Louis","year":"1974","journal-title":"J Can Assoc Radiol"},{"key":"2026080802431612500_ejhf654-bib-0198","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02841860510007440","article-title":"The pathology of ionizing radiation as defined by morphologic patterns","volume":"44","author":"Fajardo","year":"2005","journal-title":"Acta Oncol"},{"key":"2026080802431612500_ejhf654-bib-0199","first-page":"563","article-title":"Radiation-induced peripheral artery disease","volume":"72","author":"Jurado","year":"2008","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080802431612500_ejhf654-bib-0200","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","article-title":"ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)","volume":"32","author":"European Stroke Organisation","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0201","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/STROKEAHA.111.633743","article-title":"Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis","volume":"43","author":"Fokkema","year":"2012","journal-title":"Stroke"},{"key":"2026080802431612500_ejhf654-bib-0202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clon.2013.10.002","article-title":"Clinical features of radiation-induced carotid atherosclerosis","volume":"26","author":"Gujral","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026080802431612500_ejhf654-bib-0203","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000091638","article-title":"Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation","volume":"105","author":"Limsuwan","year":"2006","journal-title":"Cardiology"},{"key":"2026080802431612500_ejhf654-bib-0204","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1086\/677359","article-title":"Imatinib in pulmonary arterial hypertension: c-Kit inhibition","volume":"4","author":"Farha","year":"2014","journal-title":"Pulm Circ"},{"key":"2026080802431612500_ejhf654-bib-0205","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0206","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0207","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"2026080802431612500_ejhf654-bib-0208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0209","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0360-3016(94)00656-6","article-title":"Radiation injury to the heart","volume":"31","author":"Stewart","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802431612500_ejhf654-bib-0210","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/0002-9149(83)90209-6","article-title":"Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients","volume":"51","author":"Applefeld","year":"1983","journal-title":"Am J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0211","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802431612500_ejhf654-bib-0212","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0213","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0214","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jacc.2014.11.036","article-title":"Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation","volume":"65","author":"Ness","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0215","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2008.21.1953","article-title":"Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings","volume":"27","author":"Diller","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0216","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0217","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ijc.29468","article-title":"Cardiovascular disease in adult life after childhood cancer in Scandinavia: a population-based cohort study of 32,308 one-year survivors","volume":"137","author":"Gudmundsdottir","year":"2015","journal-title":"Int J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0218","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","volume":"22","author":"Aapro","year":"2011","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0219","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0220","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"2026080802431612500_ejhf654-bib-0221","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/pd.3847","article-title":"Effects of chemotherapy during pregnancy on the maternal and fetal heart","volume":"32","author":"Gziri","year":"2012","journal-title":"Prenat Diagn"},{"key":"2026080802431612500_ejhf654-bib-0222","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.2009.23.2801","article-title":"Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes","volume":"28","author":"Van Calsteren","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0223","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1600-0412.2012.01524.x","article-title":"Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function","volume":"91","author":"Gziri","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026080802431612500_ejhf654-bib-0224","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ygyno.2010.08.019","article-title":"Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model","volume":"119","author":"Van Calsteren","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2026080802431612500_ejhf654-bib-0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PPO.0b013e3181ce46f9","article-title":"Breast cancer during pregnancy: maternal and fetal outcomes","volume":"16","author":"Cardonick","year":"2010","journal-title":"Cancer J"},{"key":"2026080802431612500_ejhf654-bib-0226","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0227","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0228","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-11-318","article-title":"Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101\u2014Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI","volume":"11","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"2026080802431612500_ejhf654-bib-0229","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","article-title":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","volume":"65","author":"Barac","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/fca.15.55","article-title":"Cardio-oncology: a new discipline in medicine to lead us into truly integrative care","volume":"11","author":"Clarke","year":"2015","journal-title":"Future Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0231","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jacc.2015.07.033","article-title":"Burgeoning cardio-oncology programs: challenges and opportunities for early career cardiologists\/faculty directors","volume":"66","author":"Okwuosa","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0232","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026080802431612500_ejhf654-bib-0233","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","article-title":"ICRF-187 permits longer treatment with doxorubicin in women with breast cancer","volume":"10","author":"Speyer","year":"1992","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0234","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.1996.14.12.3112","article-title":"Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer","volume":"14","author":"Venturini","year":"1996","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0235","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0236","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0237","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline\u2013based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0238","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/08880018.2010.503335","article-title":"Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion","volume":"27","author":"Huh","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"2026080802431612500_ejhf654-bib-0239","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","article-title":"Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0240","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"6","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0241","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0242","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2007.12.2481","article-title":"Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane","volume":"26","author":"Barry","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0243","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0244","author":"European Medicines Agency"},{"key":"2026080802431612500_ejhf654-bib-0245","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0246","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0247","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080802431612500_ejhf654-bib-0248","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0249","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0250","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802431612500_ejhf654-bib-0251","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0252","first-page":"CD005006","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"5","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0253","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0254","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0255","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jsams.2009.03.002","article-title":"Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise","volume":"12","author":"Hayes","year":"2009","journal-title":"J Sci Med Sport"},{"key":"2026080802431612500_ejhf654-bib-0256","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0257","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/07347332.2014.955243","article-title":"Correlates of positive health behaviors in cancer survivors: results from the 2010 LIVESTRONG survey","volume":"32","author":"Low","year":"2014","journal-title":"J Psychosoc Oncol"},{"key":"2026080802431612500_ejhf654-bib-0258","first-page":"CD008465","article-title":"Exercise interventions on health-related quality of life for people with cancer during active treatment","volume":"8","author":"Mishra","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0259","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0260","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026080802431612500_ejhf654-bib-0261","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminoncol.2014.04.005","article-title":"Therapy for cancer-related thromboembolism","volume":"41","author":"Frere","year":"2014","journal-title":"Semin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0262","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"key":"2026080802431612500_ejhf654-bib-0263","first-page":"CD006468","article-title":"Anticoagulation for people with cancer and central venous catheters","volume":"10","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802431612500_ejhf654-bib-0264","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0265","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-99-6-745","article-title":"Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy","volume":"99","author":"Torti","year":"1983","journal-title":"Ann Intern Med"},{"key":"2026080802431612500_ejhf654-bib-0266","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0267","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14740338.2015.1010505","article-title":"Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma","volume":"14","author":"Boyle","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2026080802431612500_ejhf654-bib-0268","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"2026080802431612500_ejhf654-bib-0269","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2008.03.036","article-title":"Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study","volume":"135","author":"Lotrionte","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0270","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","article-title":"Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0271","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"2026080802431612500_ejhf654-bib-0272","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ijcard.2012.10.079","article-title":"Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study","volume":"167","author":"Lotrionte","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0273","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0274","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/sonc.2001.26435","article-title":"Pharmacokinetic profiles of doxorubicin in combination with taxanes","volume":"28","author":"Holmes","year":"2001","journal-title":"Semin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0275","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.106.103846","article-title":"Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies","volume":"318","author":"Salvatorelli","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2026080802431612500_ejhf654-bib-0276","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Floyd","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0277","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0278","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0279","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"2026080802431612500_ejhf654-bib-0280","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0281","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080802431612500_ejhf654-bib-0282","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026080802431612500_ejhf654-bib-0283","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0284","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"2026080802431612500_ejhf654-bib-0285","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026080802431612500_ejhf654-bib-0286","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force Members","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080802431612500_ejhf654-bib-0287","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2026080802431612500_ejhf654-bib-0288","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9343(88)80268-7","article-title":"Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers","volume":"85","author":"Oleksowicz","year":"1988","journal-title":"Am J Med"},{"key":"2026080802431612500_ejhf654-bib-0289","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/02841869009091790","article-title":"Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil","volume":"29","author":"Eskilsson","year":"1990","journal-title":"Acta Oncol"},{"key":"2026080802431612500_ejhf654-bib-0290","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2026080802431612500_ejhf654-bib-0291","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"issue":"(2 Suppl 3)","key":"2026080802431612500_ejhf654-bib-0292","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1053\/j.seminoncol.2005.03.013","article-title":"Cardiac toxicity following thoracic radiation","volume":"32","author":"Prosnitz","year":"2005","journal-title":"Semin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0293","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1118\/1.2713216","article-title":"Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry","volume":"34","author":"Louwe","year":"2007","journal-title":"Med Phys"},{"key":"2026080802431612500_ejhf654-bib-0294","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-9966-32-88","article-title":"Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer","volume":"32","author":"Bruzzaniti","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"2026080802431612500_ejhf654-bib-0295","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1118\/1.4757616","article-title":"Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife","volume":"39","author":"Xu","year":"2012","journal-title":"Med Phys"},{"key":"2026080802431612500_ejhf654-bib-0296","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.radonc.2014.11.018","article-title":"The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery","volume":"114","author":"Bartlett","year":"2015","journal-title":"Radiother Oncol"},{"key":"2026080802431612500_ejhf654-bib-0297","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2012.46.6854","article-title":"American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care","volume":"31","author":"McCabe","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(Suppl 11)","key":"2026080802431612500_ejhf654-bib-0298","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/cncr.28061","article-title":"Cardiac toxicity in cancer survivors","volume":"119","author":"Lenihan","year":"2013","journal-title":"Cancer"},{"key":"2026080802431612500_ejhf654-bib-0299","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0300","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.ejca.2015.08.011","article-title":"Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy","volume":"51","author":"de Azambuja","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026080802431612500_ejhf654-bib-0301","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1067\/mnc.2003.7","article-title":"Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era","volume":"10","author":"Mitani","year":"2003","journal-title":"J Nucl Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0302","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0303","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","article-title":"Late cardiac effects of cancer treatment","volume":"30","author":"Lenihan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0304","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0305","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2014.56.8345","article-title":"Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy","volume":"33","author":"Koppelmans","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0306","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-8140(94)90008-6","article-title":"Cardiac lesions after mediastinal irradiation for Hodgkin's disease","volume":"30","author":"Glanzmann","year":"1994","journal-title":"Radiother Oncol"},{"key":"2026080802431612500_ejhf654-bib-0307","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2012.43.0702","article-title":"Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026080802431612500_ejhf654-bib-0308","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/clc.22106","article-title":"Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center","volume":"36","author":"Copeland","year":"2013","journal-title":"Clin Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0309","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ijrobp.2009.12.054","article-title":"Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease","volume":"79","author":"Machann","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802431612500_ejhf654-bib-0310","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pcad.2010.06.002","article-title":"The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society","volume":"53","author":"Lenihan","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026080802431612500_ejhf654-bib-0311","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006490","article-title":"Cardio-oncology: it takes two to translate","volume":"5","author":"Moslehi","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026080802431612500_ejhf654-bib-0312","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2008-0137","article-title":"Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations","volume":"14","author":"Martin","year":"2009","journal-title":"Oncologist"},{"key":"2026080802431612500_ejhf654-bib-0313","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.breast.2013.04.011","article-title":"Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?","volume":"22","author":"Lu","year":"2013","journal-title":"Breast"},{"key":"2026080802431612500_ejhf654-bib-0314","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0315","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2010.07.023","article-title":"Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?","volume":"56","author":"Yoon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080802431612500_ejhf654-bib-0316","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ehjci\/jev024","article-title":"EACVI\/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI\/HFA COT Registry)\u2014EURObservational Research Program of the European Society of Cardiology","volume":"16","author":"Lancellotti","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.654","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.654","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/1\/9\/66332828\/eurjhf_19_1_9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/1\/9\/66332828\/eurjhf_19_1_9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:44:01Z","timestamp":1786171441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/1\/9\/8418990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,27]]},"references-count":316,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,27]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.654","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2016,8,27]]}}}